Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XNW 3009

Next Previous
Drug Profile

XNW 3009

Alternative Names: XNW-3009

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinovent
  • Developer Evopoint Biosciences
  • Class Antigouts; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Hyperuricaemia

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Hyperuricaemia(In volunteers) in Australia (PO)
  • 10 Sep 2024 Phase-II clinical trials in Gout (PO), prior to September 2024 (Evopoint Biosciences pipeline, September 2024)
  • 10 Sep 2024 Evopoint Biosciences plans a phase III trial for Gout (PO) (Evopoint Biosciences website, September 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top